isis pharmaceuticals and astrazeneca , page-9

Mowibble -

i'm hesitatnt to really make comparisons between deals that ISIS reaches & what ANP could reach firstly ISIS is the parent & really holds the Antisense Tech under lock, it is also a much bigger company so more room to toughen up & demand higher figures. You only have to look at the agreements reached between ISIS & Genzyme on Mipomesen in the same year that ANP licensed ATL-1102 to Teva & you can see how vastly different the cards turned.

Genzyme / ISIS was one of the biggest deals in 2008 - $325M up-front, $1.7B potential milestones as it was about to head into Phase III trials.

ANP / Teva deal on the other hand Phase II trials $2M up-front, R&D costs covered & potential $100M in milestones.

shows how hard it is to try & run comparisons with others.